Interleukin Achieves Milestone and Receives $2 Million Pre-payment
04/25/2005
Interleukin Achieves Milestone and Receives $2 Million Pre-payment
Waltham, MA, April 25, 2005 -- Interleukin Genetics, Inc. (OTCBB: ILGN) reported today that it has received its Clinical Laboratory Improvement Amendments (CLIA) certificate of registration for its DNA clinical laboratory.
As a result of this event, Interleukin has received a $2 million pre-payment for genetic tests to be processed by the company pursuant to its Distribution Agreement with Access Business Group International, an affiliate of Alticor.
“We are extremely pleased to have met another milestone in our alliance with Alticor,” said Philip R. Reilly, MD, JD, Interleukin’s Chief Executive Officer. “This is an important event for the company as we prepare for product launch.”
About Interleukin Genetics
Interleukin Genetics is a biotechnology company focused on developing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin's current programs focus on cardiovascular disease, osteoporosis, rheumatoid arthritis, endometriosis, periodontal disease and weight management. Interleukin expects that these programs will lead to products that will personalize the selection of nutritional and therapeutic products and enable the managed care industry to improve patient care and better allocate resources. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com .
Certain statements contained herein are “forward-looking” statements including statements regarding our research programs leading to diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations and our expectation that we will launch commercial products. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to maintain and operate a CLIA-certified DNA testing laboratory, our ability to complete all of our key milestones with regard to Alticor programs, our ability to make progress in advancing our core technologies, our ability to launch new commercial products and those risks and uncertainties described in our annual report on Form 10-K, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Fenel M. Eloi
Interleukin Genetics, Inc.
(781) 398-0700